posted
Tasker Capital Corporation was first formed as a publicly traded company in 1999 to manufacturer, distribute and market an oral hygiene breath drink. During that time, Tasker Capital Corporation continued its clinical research and development of future products, using its proprietary technology. Our new management team is working on launching Tasker proprietary technology into marketable and efficacious consumer and industrial products.
Tasker Products is a manufacturer, distributor and marketer of products using a unique, licensed patented process that utilizes a highly charged, acidified, yet stable and safe solution that enables copper sulfate, widely known for its bacteriostatic properties to remain active throughout a wide range of pH values. The company is continuing its clinical research and development of future products in the oral care, food processing, skin care and pet products industries. Presently the company will launch Close Call ™., the world's first clinically proven anti-microbial oral hygiene breath drink. Tasker Capital Corporation is headquartered in Danbury, Connecticut.
The overall goal of Tasker is to become synonymous with technology, innovation, and product improvements to our customers and consumers. That is precisely why we will not deviate from our product strategy, particularly in view of the fact that we will be competing in multiple product categories. Consumers will come to know that Tasker simply makes better products that have superior performance characteristics or unique benefits currently not available with competing products.
Tasker Product Receives Confirmation From FDA on Use of pHarlo Technolgy for Seafood Wednesday April 6, 1:49 pm ET - * pHarlo Seafood Applications Covered Under Existing FDA GRAS and cGMP Approvals* Company Projects Seafood Application Revenue to Begin in Third Quarter 2005
DANBURY, Conn., April 6 /PRNewswire-FirstCall/ -- Tasker Capital Corp. (OTC Bulletin Board: TKER - News), a distributor and marketer of a licensed proprietary technology that is highly effective in inhibiting pathogenic bacteria, today announced that it had received a letter from the Department of Health and Human Services of the Food and Drug Administration (FDA) confirming that the use of the pHarlo technology to control pathogenic microbe growth in seafood applications is permitted under existing FDA GRAS (generally recognized as safe) and cGMP (current good manufacturing practice) regulations.
ADVERTISEMENT Unlike the meat and poultry industry, which is effectively regulated by the United States Department of Agriculture, regulators rely on proven technologies that deliver consistent results under a variety of conditions that they can identify as generally regarded as safe (under the FDA definition) in seafood processing. Initial studies of pHarlo indicated that it was highly successful in controlling pathogenic agents on seafood. Tasker has pulled together a team consisting of highly experienced industry experts, inclusive of innovated (potential) customers, to support the further development of applications using the pHarlo technology in seafood processing. Continued testing of pHarlo for use in the fish industry will run concurrent to its ongoing progress in poultry processing. Tasker's team is focused on identifying value and delivering technology solutions that can have a profound effect on our customers' products and markets. Based on active discussions with potential customers interested in using the pHarlo technology in seafood processing, the Company projects revenue from this source to begin in the third quarter of the current year.
Robert Appleby, Tasker's president and CEO, commented, "Our development team is very active and highly focused on selected target markets, as rapid progress through customer testing and commercial scale-up continues. Success in these initial areas will spawn new opportunities across a variety of product types and processes. Increasing shelf live and lowering bacterial counts will help prevent importers and exporters from landing on the 'Detain List' that often holds products at ports of entry beyond their usable life."
James Burns, Tasker's executive vice president and chief operating office, added, "The seafood industry's variable products and diverse supply chains provide a number of entry opportunities for new applications of Tasker's product formulations. Following up on numerous opportunities generated by our presence at the Boston Seafood Show and our marketing launch at the Food Safety Summit in Washington D.C. becomes a major priority for our team." Mr. Burns concluded, "The fish and fishery industries manage an extensive amount of food with a high risk of infection caused by exposure to pathologic agents and the considerable amount of handling required in processing. Tasker's products have the unique flexibility to be effectively applied in fish and shellfish processing applications ranging from the boat to the consumer's table."
Tasker intends to focus its initial efforts on addressing the immediate needs of potential customers in the U.S. domestic fish industry after which, it plans to expand the use of its technology in the seafood industry globally.
About Tasker Products
Tasker Products is a manufacturer, distributor and marketer of products using a unique, licensed patented process that utilizes a highly charged, acidified, yet stable and safe solution that enables copper sulfate, widely known for its bacteriostatic properties to remain active throughout a wide range of pH values. The company is continuing its clinical research and development of future products in the oral care, food processing, skin care and pet products industries. Presently the company markets Close Call(TM), the world's first clinically proven anti-microbial oral hygiene breath drink. Tasker Capital Corp. is headquartered in Danbury, Connecticut. To be added to the news distribution list or to present any questions, send an email to tasker@wallstreetir.com. Additional information about Tasker is also available at www.taskerproducts.com.
This release contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statement. Actual future results and trends may differ materially from those made in or suggested by any forward-looking statements due to a variety of factors, including, for example, our ability to compete with other products in our space; the risk of unfavorable federal regulation; and the fact that our status as a development stage company makes our future unclear. Consequently you should not place undue reliance on these forward-looking statements. We discuss many of these and other risks and uncertainties in greater detail under the section entitled, "Risk Factors That May Affect Future Results" in Item 1 of the Company's Current Report on Form 10-KSB as filed with SEC.
Posts: 330 | Registered: Mar 2004
| IP: Logged |
I have it on good authority that the product actually lowers your blood alcohol level as well. It's being sold overseas and in a few NE states. I already know of some insititutional buying, this thing could really be big.
Posts: 330 | Registered: Mar 2004
| IP: Logged |
I expect it to continue to rise as they are going to start distributing Close Call in CA, and other bigger cities. Still a good entry, imho...
Posts: 330 | Registered: Mar 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
